Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine

4726 Background: We have shown previously that immunization with ONY-P1, a whole cell vaccine comprising 3 irradiated allogeneic prostate cancer cell lines, markedly increased time to disease progr...